Moderna and MSD's personalized skin cancer vaccine, mRNA-4157, combined with Keytruda therapy, has shown a 96% overall survival rate in a recent trial involving 157 patients.

The vaccine, also known as V940, triggers an immune response against cancer cells using mRNA technology similar to COVID-19 vaccines.

Patients who received the vaccine had a 49% lower risk of recurrence or death compared to those on Keytruda alone.

The study, presented at ASCO 2024, demonstrates the potential of therapeutic cancer vaccines in improving outcomes for advanced melanoma patients.

Ongoing trials are exploring the vaccine's effectiveness in other types of cancer, showcasing advancements in immunotherapy and personalized treatments for hard-to-treat cancers.